Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Could microtubule inhibitors be the best choice of therapy in gastric cancer with high immune activity: mutant DYNC1H1 as a biomarker.

Aging - 20 Nov 2020

Bai Jin, Yang BoWen, Shi Ruichuan, Shao Xinye, Yang Yujing, Wang Fang, Xiao Jiawen, Qu Xiujuan, Liu Yunpeng, Zhang Ye, Li Zhi

Abstract excerpt

Immune checkpoint blockade (ICB) has achieved unprecedented breakthroughs in various cancers, including gastric cancer (GC) with high immune activity (MSI-H or TMB-H), yet clinical benefits from ICB were moderate. Here we aimed to identify the most appropriate drugs which can improve outcomes in GC. We firstly compared MSI-H and TMB-H GC samples with normal samples in TCGA-STAD cohort, respectively. After that,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Computational Biology

Share to Cytoplasmic Dyneins

Share to Drug Discovery

Share to Stomach Neoplasms

Share to Transcriptome

Share to Tubulin Modulators

Source

Open in PubMed Open full text

Identifiers

PMID: 33221769
DOI: 10.18632/aging.104084
PMCID: PMC7803585

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Could microtubule inhibitors be the best choice of therapy in gastric cancer with high immune activity: mutant DYNC1H1 as a biomarker.PMID 33221769Read ↗

The prognostic and immune significance of KIF3C in pan-cancer and its relationship with malignant progression of gastric cancerSemantic proximity Read ↗

Somatic mutation of DNAH genes implicated higher chemotherapy response rate in gastric adenocarcinoma patientsSemantic proximity Read ↗

MAP7D2 reduces CD8+ cytotoxic T lymphocyte infiltration through MYH9-HMGB1 axis in colorectal cancerSemantic proximity Read ↗

Morin Modulates Key Targets and Pathways Associated with Gastric Cancer: Network Pharmacology, Molecular Docking, Molecular Dynamics, ADMET, and In‑Vitro AnalysisSemantic proximity Read ↗

Investigation on potential biomarkers of hyperprogressive disease (HPD) triggered by immune checkpoint inhibitors (ICIs).Semantic proximity Read ↗

Diagnostic Biomarker KIF23 is Associated With Immune Infiltration in Gastric CancerSemantic proximity Read ↗

PTCH1 mutation as a potential predictive biomarker for immune checkpoint inhibitors in gastrointestinal cancer.Semantic proximity Read ↗

DYNC2H1 mutation as a potential predictive biomarker for immune checkpoint inhibitor efficacy in NSCLC and melanoma.Semantic proximity Read ↗

The genomic and immune landscapes of gastric cancer and their correlations with HER2 amplification and PD-L1 expression.Semantic proximity Read ↗

Elevated TUBA1A Might Indicate the Clinical Outcomes of Patients with Gastric Cancer, Being Associated with the Infiltration of Macrophages in the Tumor Immune Microenvironment.Semantic proximity Read ↗

Pan-cancer evaluation of clinical value of mitotic network activity index (MNAI) and its predictive value of immunotherapySemantic proximity Read ↗

α-Tomatine Inhibits Proliferation, Metastasis, Drug Resistance and Immune Infiltration Through the PI3K-AKT-MAPK Axis in Gastric CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.